Next Phase Newsletter

The Foundation has helped to organize, and is a General Partner of, the Venture Fund, a $350 million fund focused on pre-clinical, Phase I, Phase II, and Phase III investments. The Fund executed a first close by June 2018, and a second close by early 2019.

The Fund invests primarily within the United States, but have a small allocation for foreign investments.

Sector interests include drugs, medical devices, and novel approaches. The firm is also open to funding technologies designed to accelerate cancer research and drug development, such as novel drug discovery tools or algorithms. The firm finances projects from the early discovery stage through to Phase III clinical trials. The foundation considers projects in any type of cancer.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

A publicly NASDAQ-traded diagnostics company with operations in China and the United States specializes in pre-cancer and cancer screening based on biophysical properties. The firm is looking to partner or acquire a majority share in early stage companies in the diagnostics space. While the firm is looking to be the majority stakeholder in these companies, the firm is most interested in continuing a partnership/joint venture with these startups, as opposed to a full acquisition. The firm is willing to partner globally.

The firm is interested in diagnostics companies only. Within diagnostics, the firm is interested in two types of partnerships. First, the firm is seeking oncology diagnostics that use genetic or biomarker identification of specific cancer types that can be paired with their technology, meshing the specific genetic/biomarker for these cancers with the biophysical anomalies they detect. Additionally, the firm is also looking to partner with companies in the oncology space that are seeking to expand to China and can take advantage of the firm’s existing infrastructure. For these partnerships, the firm is interested in all forms of diagnostics in all indications.

The firm is looking to acquire at least a 51% stake in the companies with which they are partnering, but is open to any structures that are advantageous for all parties. As a partner, the firm has facilities in place for any additional research or clinical tests needed to help companies reach commercialization in the United States, as well as the ability to help with distribution, especially in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the USA makes around 1/3 of its investments in industry tech mainly focusing on digital transformation within traditional sectors, second 1/3 in enterprise tech including both SaaS and network technology, and the last 1/3 in healthcare , including AI in healthcare and medical devices.

The firm typically invests $1M-$2M initial check per company,  and reserve 2/3 of the fund for pro rata. The firm prefers to lead the round and also open to co-investment. The firm typically makes 7-10 new investments per year, and only focuses on companies based in North America (USA & Canada). Furthermore, the firm has a considerable value-add in supporting companies leveraging their former entrepreneur and operator experience, and their CXO network which includes over 30 executives from Fortune 1000 companies.

The firm is open to all subsectors of AI in healthcare, diagnostics and all classes of medical devices. The firm is indication agnostic and looks primarily at early-stage companies, particularly at the seed and pre-Series A stage.

The firm does not have a particular management team requirement, as it primarily assesses the technology itself. If leading the round, the firm will take a board seat after an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Western Europe based venture capital firm provides university spin-offs as well as other promising start-up companies with capital, coaching and networks. The firm is an advisor to multiple funds, and is investing in a variety of technological industries; about 50% of the portfolio is in the life science sector. The firm makes allocations from $500,000 to $10M over the life of the investment, and in the life science sector allocations are typically over $5m. The firm primarily invests in companies based in Europe or with ties to Europe. Allocations to US, Canada and Israel are possible.

The firm invests in the biotech and medtech sectors and is opportunistic within these sectors regarding indication area and technology. The firm prefers to invest in early-stage companies, with assets ranging from preclinical to mid-stage clinical trials (Phase II for therapeutics).

The firm seeks highly qualified, ambitious management teams, and is typically an activist investor that takes a seat on a portfolio company’s board.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.